In the United States<unk>  is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone. In the European Union<unk>  is indicated for the treatment of people with type 2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of<unk>  and<unk> .
Pioglitazone/glimepiride
Pioglitazone/metformin
Insulin degludec/liraglutide
Glibenclamide/metformin
Canagliflozin/metformin
Dapagliflozin/saxagliptin
Empagliflozin/linagliptin
Empagliflozin/metformin